Neuropeptides in 2026: Where the Research Actually Stands

Semax, Selank, Cerebrolysin, and Dihexa — separating clinical evidence from online hype in the cognitive enhancement space.

Trend Report7 min readMarch 9, 2026

The Neuropeptide Landscape Is Uneven

Cognitive enhancement peptides occupy a wide spectrum of evidence quality. At one end, you have Cerebrolysin — a porcine brain-derived peptide mixture with over 30 clinical trials including large-scale RCTs in stroke and dementia. At the other, you have Dihexa — a fascinating molecule with potent preclinical activity but essentially zero human data. Understanding where each neuropeptide falls on this spectrum is essential for making informed decisions. The online peptide community often treats these compounds as interchangeable nootropics, but the evidence profiles are dramatically different.

Cerebrolysin: The Most Studied Neuropeptide

Cerebrolysin has been used clinically in Europe and Asia for decades, with a substantial evidence base: • A Cochrane-level systematic review evaluated its use in acute ischemic stroke, finding evidence of neurological improvement but noting methodological limitations in many trials. • Multiple RCTs in vascular dementia and Alzheimer's disease have shown modest cognitive benefits, particularly in combination with standard therapies. • The mechanism involves neurotrophic factor mimicry — Cerebrolysin contains fragments that activate the same pathways as BDNF and NGF. • A 2011 RCT evaluated combination treatment with Cerebrolysin and donepezil in Alzheimer's patients, finding the combination superior to donepezil alone on cognitive measures. • A 2022 RCT further showed that Cerebrolysin plus donepezil modulates amyloid-beta and tau biomarkers in neuronal-derived extracellular vesicles — providing a mechanistic window into how it may work in AD. The limitation: despite extensive clinical use, Cerebrolysin hasn't achieved FDA approval in the US, partly because the exact composition is difficult to standardize (it's a mixture, not a single compound) and partly due to study quality concerns. The 2023 Cochrane review update on Cerebrolysin for acute ischaemic stroke found some evidence of benefit but continued to note methodological limitations. It's approved in over 40 countries but remains unlicensed in the US and UK.

Semax and Selank: The Russian Clinical Data

Semax and Selank were developed at the Institute of Molecular Genetics in Moscow and are approved medications in Russia. Their clinical evidence is real but comes with a caveat: most trials are published in Russian-language journals, making independent verification difficult for English-speaking researchers. Semax (an ACTH analog) has RCT data in stroke recovery and cognitive impairment, showing improvements in neurological outcomes. Clinical trials dating from 1997 through 2018 have evaluated Semax at different stages of ischemic stroke with positive results. Selank (a tuftsin analog) has RCT data in generalized anxiety disorder and neurasthenia, showing anxiolytic effects comparable to benzodiazepines without sedation or dependence. A head-to-head trial compared Selank to phenazepam (a benzodiazepine), finding comparable anxiolytic efficacy with a better tolerability profile. The modified forms — NA-Semax-Amidate and N-Acetyl Selank Amidate — are popular in the peptide community for their enhanced bioavailability, but have less direct clinical data than the parent compounds.

Dihexa and PE-22-28: Preclinical Promise

Dihexa generated enormous excitement when a 2013 paper showed it was seven orders of magnitude more potent than BDNF at promoting synaptogenesis in cell culture. In animal models, it improved cognitive function in aged rats at picomolar doses. PE-22-28, derived from the spadin peptide, targets the TREK-1 potassium channel and shows antidepressant and procognitive effects in animal models. The original 2010 discovery of spadin as a TREK-1 blocker with antidepressant properties was published in PLoS Biology, and a 2019 review in Pharmacology & Therapeutics surveyed the growing body of evidence around TREK-1 as a depression target. Both compounds are genuinely interesting scientifically. But neither has human trial data, and the leap from "potent in a petri dish" to "effective and safe in humans" is enormous. Dihexa's extraordinary potency at HGF/c-Met signaling actually raises safety questions — the same pathway is involved in cancer cell proliferation.

Making Sense of the Evidence Tiers

Here's how we'd rank the neuropeptide evidence as of 2026: • Tier 1 (Clinical evidence): Cerebrolysin — multiple RCTs, approved in 40+ countries • Tier 2 (Regional clinical evidence): Semax, Selank — RCTs exist but primarily in Russian literature • Tier 3 (Strong preclinical): Dihexa, PE-22-28 — compelling animal data, no human trials • Tier 4 (Derivative): NA-Semax-Amidate, N-Acetyl Selank Amidate — enhanced forms with less direct evidence If you're evaluating neuropeptides, this hierarchy matters. Starting with the best-evidenced options and working down is always more rational than choosing based on online enthusiasm alone.

Key Findings

Cerebrolysin has the strongest evidence base with multiple RCTs in stroke and dementia, approved in 40+ countries
Semax and Selank have genuine RCT data from Russian clinical programs, showing neurological and anxiolytic benefits
Dihexa is 10 million times more potent than BDNF in vitro but has zero human data
The gap between the most and least evidence-supported neuropeptides is enormous — they should not be treated as equivalent
The 2023 Cochrane review update continues to find evidence of neurological improvement with Cerebrolysin in acute ischaemic stroke, though methodological concerns persist
Cerebrolysin combined with donepezil showed superior outcomes to donepezil alone in Alzheimer's RCTs, with biomarker evidence of amyloid-beta and tau modulation
Selank demonstrated anxiolytic efficacy comparable to the benzodiazepine phenazepam in a head-to-head clinical trial, with a better tolerability profile
TREK-1 channel blockade (the PE-22-28 mechanism) is supported by knockout mouse studies, pharmacological data, and human biomarker studies linking sortilin-derived propeptide levels to depression

Limitations & Caveats

Most Cerebrolysin trials have methodological limitations noted in systematic reviews
Semax/Selank clinical data is primarily in Russian-language journals, limiting independent verification
Dihexa's potent HGF/c-Met activity raises theoretical oncogenic safety concerns
Modified forms (NA-Semax-Amidate, N-Acetyl Selank Amidate) have less direct clinical data than parent compounds
Dihexa's preclinical data comes primarily from a single research group at Washington State University, with limited independent replication
PE-22-28 and spadin analogs have no human clinical trials; all antidepressant evidence is from animal models
Cerebrolysin's composition as a peptide mixture (not a single compound) makes standardization and FDA-style approval inherently challenging

Sources

[The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]

Randomized Controlled Trial2008

[Optimization of the treatment of anxiety disorders with selank]

Randomized Controlled Trial2015

Cerebrolysin for acute ischaemic stroke

Systematic Review2023Cochrane Database Syst Rev

Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials

Meta-Analysis2015Dement Geriatr Cogn Disord

Cerebrolysin: a review of its use in dementia

Review2009Drugs Aging

Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil

Randomized Controlled Trial2011Curr Alzheimer Res

[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]

Randomized Controlled Trial2008Zh Nevrol Psikhiatr Im S S Korsakova

[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]

Clinical Trial1997Zh Nevrol Psikhiatr Im S S Korsakova

The efficacy of semax in the treatment of patients at different stages of ischemic stroke

Clinical Trial2018Zh Nevrol Psikhiatr Im S S Korsakova

10.

Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents

Preclinical2013J Pharmacol Exp Ther

11.

Contributions by the Brain Renin-Angiotensin System to Memory, Cognition, and Alzheimer's Disease

Review2019J Alzheimers Dis

12.

Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design

Preclinical2010PLoS Biol

13.

Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin

Review2019Pharmacol Ther

Peptides in This Article

Semax

EmergingNootropic Peptide

Selank

EmergingNootropic Peptide

Cerebrolysin

StrongNeurotrophic Peptide Complex

Dihexa

PreliminaryAngiotensin Analog

NA-Semax-Amidate

LimitedNootropic Peptide

N-Acetyl Selank Amidate

EmergingNootropic Peptide

PE-22-28

PreliminaryNeuroactive Peptide

Neuropeptides in 2026: Where the Research Actually Stands

The Neuropeptide Landscape Is Uneven

Cerebrolysin: The Most Studied Neuropeptide

Semax and Selank: The Russian Clinical Data

Dihexa and PE-22-28: Preclinical Promise

Making Sense of the Evidence Tiers

Key Findings

Limitations & Caveats

Sources

Peptides in This Article

Related Reading